{"ticker": {"uuid": "ddccad79-0c20-424c-bb9f-06a8e9783ecd", "symbol": "EOLS", "name": "Evolus Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Drug Manufacturers - Specialty & Generic"}, "articles": [{"title": "Analysts Conflicted on These Healthcare Names: Irhythm Technologies (IRTC), Penumbra (PEN) and Evolus (EOLS)", "summary": "This article highlights recent analyst ratings for several healthcare companies. Irhythm Technologies (IRTC) received a \"Strong Buy\" consensus with a significant upside, while Penumbra (PEN) garnered a \"Hold\" consensus. Evolus (EOLS) also received a \"Strong Buy\" consensus rating ", "url": "https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/3293172/analysts-conflicted-on-these-healthcare-names-irhythm-technologies-irtc-penumbra-pen-and-evolus-eols/", "source_name": "The Globe and Mail", "published_at": "2026-07-15T12:12:27", "published_display": "15 Jul 2026 12:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evolus issues stock-based hiring incentives to 38 new employees", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQU0dmSzJoQ2xVRDdMTm54TmVqQWV2VnR4Nm9Kbm1FTUZWdnp0Q28wWUtTTU9HT0RFR3ZvMXFWNk55eXFOTGRiaDdiWEZ4LXpDQWpNZ2wtVVhYUUxvVnQtUmVyQUdJcEdLYUsyUUY4NUJ3VllSVEN0UUtNZlM2cnh2Y2ZjX2wtaFlnbExZQTRxV3ZpdHU4Rm1sN3RoRGd3MmJnNVlpRDRERWU2TnhGajVRc19naHhfSVlmVGJMOA?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-10T20:05:00+00:00", "published_display": "10 Jul 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "Evolus, Inc. announced the grant of 115,000 restricted stock units (RSUs) to 38 newly hired non-executive employees between April and July 2026. These inducement awards were approved by the compensation committee under Evolus' 2023 Inducement Incentive Plan, as material inducemen", "url": "https://ca.finance.yahoo.com/news/evolus-reports-inducement-grants-under-200500197.html", "source_name": "Yahoo! Finance Canada", "published_at": "2026-07-10T16:05:00", "published_display": "10 Jul 2026 16:05", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evolus Class Action Reminder", "summary": "Faruqi & Faruqi, LLP is reminding investors who suffered losses exceeding $100,000 in Evolus (NASDAQ: EOLS) stock or options between February 1, 2019, and July 6, 2020, to contact them. The firm is investigating potential claims that Evolus made misleading statements regarding it", "url": "https://www.newsfilecorp.com/release/69495?lang=fr", "source_name": "TMX Newsfile", "published_at": "2026-07-10T08:39:56", "published_display": "10 Jul 2026 08:39", "sentiment": "negative", "sentiment_pct": 28, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in Evolus, Inc. Stocks", "summary": "This article lists various ETFs that invest in Evolus, Inc. (EVL) stocks, providing details such as market value, weight, issuer, management style, expense ratio, and AUM. The funds primarily focus on small-cap, total market, micro-cap, and healthcare sectors, offering investors ", "url": "https://www.tradingview.com/symbols/FWB-EVL/etfs/", "source_name": "TradingView", "published_at": "2026-07-09T08:40:45", "published_display": "09 Jul 2026 08:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evolus Partners With IBSA to Develop, Commercialize Profhilo in US", "summary": "Evolus has partnered with IBSA to develop and commercialize Profhilo, an injectable aesthetic treatment, in the United States. This collaboration aims to bring a new bio-remodeling product to the US market, expanding Evolus's portfolio beyond neuromodulators and adding an immedia", "url": "https://www.moomoo.com/news/post/72656750/evolus-partners-with-ibsa-to-develop-commercialize-profhilo-in-us", "source_name": "Moomoo", "published_at": "2026-07-09T03:39:41", "published_display": "09 Jul 2026 03:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evolus, IBSA Partner to Develop and Commercialize Skin Quality Filler in the US", "summary": "Evolus has entered into an exclusive licensing and distribution agreement with IBSA to develop and commercialize Profhilo, a hyaluronic acid-based injectable for skin quality improvement, in the United States. This partnership expands Evolus's presence in the aesthetic market, ta", "url": "https://thedermdigest.com/evolus-ibsa-partner-to-develop-and-commercialize-skin-quality-filler-in-the-us/", "source_name": "The Dermatology Digest", "published_at": "2026-07-08T15:39:43", "published_display": "08 Jul 2026 15:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evolus signs licensing deal for Profhilo skin injectable in US", "summary": "Evolus Inc. has signed an exclusive licensing and distribution agreement with IBSA to commercialize Profhilo, a hyaluronic acid skin injectable, in the United States. This agreement allows Evolus to expand its aesthetic product portfolio, complementing its existing neurotoxin and", "url": "https://www.investing.com/news/company-news/evolus-signs-licensing-deal-for-profhilo-skin-injectable-in-us-93CH-4781771", "source_name": "Investing.com", "published_at": "2026-07-08T13:39:43", "published_display": "08 Jul 2026 13:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evolus signs licensing deal for Profhilo skin injectable in US By Investing.com", "summary": "Evolus Inc. has signed an exclusive licensing and distribution agreement with Swiss pharmaceutical company IBSA to bring Profhilo, a hyaluronic acid skin injectable, to the United States. This strategic move expands Evolus's aesthetic product portfolio, which already includes Jeu", "url": "https://ca.investing.com/news/stock-market-news/evolus-signs-licensing-deal-for-profhilo-skin-injectable-in-us-93CH-4725402", "source_name": "Investing.com Canada", "published_at": "2026-07-08T13:18:04", "published_display": "08 Jul 2026 13:18", "sentiment": "positive", "sentiment_pct": 73, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evolus Secures Exclusive U.S. Profhilo License From IBSA; No Upfronts, 15-Year Term", "summary": "Evolus has secured an exclusive 15-year U.S. license, supply, and distribution agreement with IBSA for Profhilo, an injectable hyaluronic acid product for skin quality. Evolus will manage the U.S. development, clinical work, and regulatory approval, with no upfront or milestone p", "url": "https://www.tradingview.com/news/tradingview:1ae7b95f4c814:0-evolus-secures-exclusive-u-s-profhilo-license-from-ibsa-no-upfronts-15-year-term/", "source_name": "TradingView", "published_at": "2026-07-08T13:13:04", "published_display": "08 Jul 2026 13:13", "sentiment": "positive", "sentiment_pct": 71, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evolus adds Profhilo, a skin-quality injectable sold in 70+ countries", "summary": "Evolus, Inc. announced an exclusive licensing and distribution agreement with IBSA to bring Profhilo\u00ae, a leading skin-quality injectable, to the United States. This partnership expands Evolus's injectable portfolio into the rapidly growing skin quality segment, complementing its ", "url": "https://www.stocktitan.net/news/EOLS/evolus-announces-partnership-with-ibsa-to-develop-and-commercialize-vtkgy75cjupb.html", "source_name": "Stock Titan", "published_at": "2026-07-08T13:12:04", "published_display": "08 Jul 2026 13:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evolus Announces Partnership with IBSA to Develop and Commercialize Market-Leading Profhilo\u00ae in the United States, Expanding Its Injectable Portfolio into Skin Quality", "summary": "Evolus, Inc. has partnered with IBSA to exclusively license and commercialize Profhilo\u00ae in the United States, expanding Evolus's injectable portfolio into the skin quality segment. Profhilo\u00ae is a market-leading injectable in Europe designed to improve skin quality, hydration, ela", "url": "https://ca.finance.yahoo.com/news/evolus-announces-partnership-ibsa-develop-130000914.html", "source_name": "Yahoo! Finance Canada", "published_at": "2026-07-08T09:00:00", "published_display": "08 Jul 2026 09:00", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(EOLS) and the Role of Price-Sensitive Allocations", "summary": "This article provides an analysis of Evolus Inc. (NASDAQ: EOLS) based on AI-generated signals for July 7, 2026. It highlights a near-term weak sentiment but mid-term strength within a broader long-term weak bias, noting compelling upside potential due to the absence of resistance", "url": "https://news.stocktradersdaily.com/news_release/52/EOLS_and_the_Role_of_Price-Sensitive_Allocations_070726031602_1783408562.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-07T03:16:49", "published_display": "07 Jul 2026 03:16", "sentiment": "negative", "sentiment_pct": 35, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EOLS - Evolus Inc Options", "summary": "This page provides a detailed financial overview of Evolus Inc (EOLS) options, including its latest stock price, financial metrics, and performance indicators. It covers market capitalization, income, sales, various ratios, insider ownership, institutional ownership, profitabilit", "url": "https://finviz.com/quote?t=EOLS&ta=1&p=m&ty=oc&r=y5&ov=list_strike&s=2.5", "source_name": "Finviz", "published_at": "2026-07-06T19:11:49", "published_display": "06 Jul 2026 19:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Evolus, Inc. Common Stock \u2013 NASDAQ:EOLS", "summary": "This page from TradingView provides financial information for Evolus, Inc. Common Stock (NASDAQ: EOLS), specifically focusing on its enterprise value to EBITDA forward metric. It highlights the company's financial overview within the health technology and pharmaceutical sectors. ", "url": "https://www.tradingview.com/symbols/NASDAQ-EOLS/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T13:09:39", "published_display": "28 Jun 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evolus (EOLS) price target decreased by 11.11% to 14.96", "summary": "The price target for Evolus (EOLS) has been decreased by 11.11%, bringing it down to $14.96. Further details are not available in the provided content.", "url": "http://www.msn.com/en-us/money/topstocks/evolus-eols-price-target-decreased-by-11-11-to-14-96/ar-AA1X5JEh?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "source_name": "MSN", "published_at": "2026-06-28T11:09:27", "published_display": "28 Jun 2026 11:09", "sentiment": "negative", "sentiment_pct": 30, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evolus, Inc. Actuals & Estimates (NASDAQ:EOLS)", "summary": "This article provides actuals and estimates for Evolus, Inc. (NASDAQ:EOLS), including financial data, analyst forecasts, and various stock performance metrics. It covers the company's current stock price, historical highs and lows, volatility, market capitalization, and earnings ", "url": "https://www.tradingview.com/symbols/NASDAQ-EOLS/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T09:11:19", "published_display": "26 Jun 2026 09:11", "sentiment": "positive", "sentiment_pct": 61, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Evolus, Inc. Common Stock \u2013 NASDAQ:EOLS", "summary": "This article provides access to the \"Price to sales forward\" financial metric for Evolus, Inc. Common Stock (NASDAQ: EOLS) on the TradingView platform. It highlights that this data is part of the financials section for EOLS, indicating its availability for users analyzing the com", "url": "https://www.tradingview.com/symbols/NASDAQ-EOLS/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T09:09:46", "published_display": "26 Jun 2026 09:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EOLS Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "The article provides a forecast and price target for Evolus, Inc. (EOLS) stock for 2027, based on analyst ratings and the company's financial performance. It includes current stock price information, historical highs and lows, market capitalization, volatility, and details on ear", "url": "https://www.tradingview.com/symbols/NASDAQ-EOLS/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T16:09:20", "published_display": "25 Jun 2026 16:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evolus Inc (EOLS) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Evolus Inc (EOLS), detailing its price momentum score of 9.32 within the Pharmaceuticals industry. It identifies current support at $6.35 and resistance at $7.55, suggesting suitability for range-bound swing trading. The analysis incl", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-eols/technical", "source_name": "TradingKey", "published_at": "2026-06-24T09:09:20", "published_display": "24 Jun 2026 09:09", "sentiment": "positive", "sentiment_pct": 77, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Evolus (EOLS) Finally Turning the Corner on Profitability", "summary": "Evolus (EOLS) reported strong Q1 2026 results, beating revenue expectations with $73.1 million, driven by demand for Jeuveau and growth in Evolisse. The company achieved its second consecutive quarter of positive Adjusted EBITDA, signaling progress toward full-year profitability ", "url": "https://www.kavout.com/market-lens/is-evolus-eols-finally-turning-the-corner-on-profitability", "source_name": "Kavout", "published_at": "2026-06-21T00:40:43", "published_display": "21 Jun 2026 00:40", "sentiment": "positive", "sentiment_pct": 63, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evolus Inc (EOLS) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Evolus Inc (EOLS) has a financial score of 8.00, placing it 84th out of 157 in the Pharmaceuticals industry, indicating a weak financial status but high operating efficiency. The company reported a quarterly revenue of $73.14M, marking a 6.74% year-over-year increase, and net pro", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-eols/financial-health", "source_name": "TradingKey", "published_at": "2026-06-18T19:09:32", "published_display": "18 Jun 2026 19:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evolus Inc (EOLS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "The article provides a revenue breakdown for Evolus Inc (EOLS). However, it states that relevant data regarding business segments, regional revenue, and profit contribution have not been disclosed by the company yet. The page displays current stock information for EOLS, including", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-eols/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T11:40:39", "published_display": "18 Jun 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evolus Inc (EOLS) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Evolus Inc (EOLS), identifying major shareholders by proportion and type, as well as institutional holdings over various quarters. It highlights key individual and institutional investors and their recent activities, alongside rel", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-eols/ownership", "source_name": "TradingKey", "published_at": "2026-06-18T11:40:39", "published_display": "18 Jun 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evolus Inc (EOLS) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Evolus Inc (EOLS) has an earnings forecast score of 8.57, ranking 28th in the Pharmaceuticals industry. Analysts have a consensus \"Buy\" rating for EOLS, with an average price target of $19.50, suggesting a significant upside of over 121% from its current price of $6.63. The expec", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-eols/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T06:40:44", "published_display": "18 Jun 2026 06:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EOLS Reiterated by BTIG -- Price Target Maintained at $13.00", "summary": "BTIG has reiterated a Buy rating for Evolus (EOLS), maintaining a price target of $13.00. Despite strong growth potential (GF Score Growth 10/10), the company faces challenges in Financial Strength and Profitability (both 3/10). The stock is considered 51.0% undervalued by GuruFo", "url": "https://www.gurufocus.com/news/8920352/eols-reiterated-by-btig-price-target-maintained-at-1300", "source_name": "GuruFocus", "published_at": "2026-06-17T11:10:39", "published_display": "17 Jun 2026 11:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evolus Inc (EOLS) Institutional Confidence", "summary": "Evolus Inc (EOLS) has an institutional shareholding score of 7.00, ranking 51st in the Pharmaceuticals industry. The institutional shareholding proportion is 75.98%, a decrease of 14.84% quarter-over-quarter. James Simons is the largest institutional shareholder, with other signi", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-eols/sentiment", "source_name": "TradingKey", "published_at": "2026-06-17T05:40:04", "published_display": "17 Jun 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[EFFECT] Evolus, Inc. SEC Filing", "summary": "This article provides details on an SEC filing (Form EFFECT) by Evolus, Inc. The filing indicates an effectiveness date of June 12, 2026, for Form S-3. It also includes company information, recent news, and other SEC filings for Evolus.", "url": "https://www.stocktitan.net/sec-filings/EOLS/effect-evolus-inc-sec-filing-aca2df6814a4.html", "source_name": "Stock Titan", "published_at": "2026-06-15T10:39:29", "published_display": "15 Jun 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Understanding the Setup: (EOLS) and Scalable Risk", "summary": "This article provides an analysis of Evolus Inc. (NASDAQ: EOLS) using AI models to suggest trading strategies. It highlights mixed sentiment, potential upside due to lack of resistance, and offers specific position trading, momentum breakout, and risk hedging strategies. The anal", "url": "https://news.stocktradersdaily.com/news_release/89/Understanding_the_Setup:_EOLS_and_Scalable_Risk_061526125602_1781499362.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-15T00:56:00", "published_display": "15 Jun 2026 00:56", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evolus shareholders re-elect directors and approve executive compensation", "summary": "Evolus Inc. shareholders re-elected Brady Stewart and Vikram Malik as Class II directors for three-year terms and ratified Ernst & Young LLP as the independent public accounting firm. Shareholders also approved the compensation of the company\u2019s named executive officers in an advi", "url": "https://www.investing.com/news/sec-filings/evolus-shareholders-reelect-directors-and-approve-executive-compensation-93CH-4740826", "source_name": "Investing.com", "published_at": "2026-06-14T19:09:32", "published_display": "14 Jun 2026 19:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evolus (EOLS) shareholders approve directors, auditor and say-on-pay at 2026 meeting", "summary": "At its Annual Meeting of Stockholders held on June 11, 2026, Evolus, Inc. (EOLS) shareholders elected Brady Stewart and Vikram Malik as Class II directors, with terms extending until the 2029 annual meeting. They also ratified Ernst & Young LLP as the independent registered publi", "url": "https://www.stocktitan.net/sec-filings/EOLS/8-k-evolus-inc-reports-material-event-7482311af61b.html", "source_name": "Stock Titan", "published_at": "2026-06-12T20:38:50", "published_display": "12 Jun 2026 20:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evolus Plans to Launch Estyme Collection in Europe", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/evolus-plans-launch-estyme-collection-142513501.html", "source_name": "MT Newswires", "published_at": "2026-05-11T14:25:13+00:00", "published_display": "11 May 2026 14:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evolus to launch Estyme dermal filler line in Europe on May 16", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOVnJrTVVySFlqQUFTbTVuQVNXVUtNZGp5bDZBWG1zbF9Rd0E1V1ZyZWxqTnB4Qk81UzF1S2d1VUFLYmdyUXBPWEpjR3BaNGlkTVlkUDJteHpuMjF3cGQycU9iem5uajNqQk1jSFVNYTNsbkdZUXZLZFlKZWpsejEwWVdwb1V1NWRjaGt2OWc3eVdKa1FMdzlHSDFGQTMyeWo2U3AwQ1RScFZub25DRHRfdUJlQ1gtTThvQ1Y4?oc=5", "source_name": "Investing.com", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evolus, Inc. Q1 2026 Earnings Call Summary", "summary": "", "url": "https://finance.yahoo.com/m/02339c0c-0620-3614-a7ae-b68d46cb3b0b/evolus%2C-inc.-q1-2026-earnings.html", "source_name": "Moby", "published_at": "2026-05-05T00:23:54+00:00", "published_display": "05 May 2026 00:23", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evolus Q1 Earnings Call Highlights", "summary": "", "url": "https://finance.yahoo.com/m/a1fbc5e2-9ec3-3a6c-8d00-3977a3afbf67/evolus-q1-earnings-call.html", "source_name": "MarketBeat", "published_at": "2026-05-04T22:17:52+00:00", "published_display": "04 May 2026 22:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evolus (EOLS) Q1 2026 Earnings Transcript", "summary": "", "url": "https://finance.yahoo.com/m/61dbbb24-c13d-35a2-856d-7bbf930dce7a/evolus-%28eols%29-q1-2026.html", "source_name": "Motley Fool", "published_at": "2026-05-04T21:53:43+00:00", "published_display": "04 May 2026 21:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evolus (EOLS) Q2 2025 Earnings Call Transcript", "summary": "", "url": "https://finance.yahoo.com/m/97448adc-f08c-361f-8fda-4e68842d74db/evolus-%28eols%29-q2-2025.html", "source_name": "Motley Fool", "published_at": "2026-05-04T20:34:49+00:00", "published_display": "04 May 2026 20:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evolus Reports First Quarter 2026 Financial Results; Company Delivers Second Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year Outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwJBVV95cUxNRS1sSEUyQlRsNzlPNk5zRG4zNlJLU3U2NlBhYmdRc0V1cmFyZ0ZZWG53aW5lTFRybkFwMXduNUtFYl80WmJMRkQ1c1RiUmRtSklQWjR4SlJ3blpIWkx6RUNjQ19pbVdrdl8zXzBtYUtEdGwwaWJpMURIV3MwcDJqblpZYlRLa1A5eHVBcC1iaUozTDBHWTZKMnJfMlJQZkNsb1AwY0dYUElxanlRazRRQU5oUFktcnlibEpRU19iWE1abVBQT1BXbXVtTjRwS3pTSjI1ejd1ZUM3dzMwTHpWTWRYZExiRmFxbll4SWUxbTRRV0FnSEVxdHdMZ0hacWtZdXk3LVpPdHlVeHd1QUZSSXJxS1dxNng2ekp6REQ3cjROMVdZQUgzQnRKbzNCSzZUMDVwZFVYSQ?oc=5", "source_name": "Business Wire", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evolus, Inc. (EOLS) Reports Q1 Loss, Tops Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxQbVpHZS1CTWVmeG1zbFdCT0Y0U2JfcWkxU05HOWdCb0FpeUdULWZMV1VVdE8tRXp0WFVrdkJzRWpWU19jVmxvc1ZKRXlqWWZQM3IwYzRRaXBEeFkwR09EU2dsenZxblczcDJHSnZSYzNiSzNrNVdWY1VPWUhQMUJUeU4tMEc5c015T0hEM0MxdkpFTTZPVXc?oc=5", "source_name": "Market source", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evolus Inc. (EOLS) stock falls on Q1 2026 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxQYjZXRF9ZTG1sRWQ5bmhpbWllSnkzbHFCUDVjaUxNVUxJWEhfeERpOXkyaHBZOHB5ekdEbHA5RW9ZWDBhVFFvbFluTFlRM0NOSTZwU2JjTjJUeFdWbmhLLVdCVS1QNlpYem5TWnRaX2dJOHlTcVJDTk9reEpVU01BN2dOS0NtMHZad1hCUjRlMGo?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 22, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Evolus (EOLS) Story Is Shifting As Analysts Reset Growth And Valuation Assumptions", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxNcFJsUG1iQnVVamM1UW1ldm5LdVFZVnpaMlZhOWp5YU9jMmZuQjVGa3NROFJtZWJzdFNSV1lfcWZqTXV3MkRtU2V4SkxTc0xJSkZaV3M5Rm40N0dMVnhRSWhxbWlDNk1MZ2Fja0pGb1ZLM2JqNjJvU09JZkNEZ3hpTEhlVHR5anRPZks4ZlR2SHQ5SGFVbl9JQS0ydWN1Tkl1UVE?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Evolus (EOLS) Investment Story Is Shifting After Softer Guidance And Target Cuts", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQd3NJMzFxckwtRUZ3T1pEb1BlUVA3YkUxWXdqM3ppYTluTEdBUFJFUkdoVGFZR2hpZnQ3R1ZabDFQajdvZHZNdWhBTEhBQnJwTVQ0NWpJQlNQSGJvZnRMdko1ZjFNUTBLVWtxbE9iVzdUYmIyMElQUjFpbDF6bGpTeU5aZHhtXzg5aFltY1E4eFFHWGFyQUY0NlpzVWZIRVRxQnhvTw?oc=5", "source_name": "Market source", "published_at": "2026-04-11T07:00:00+00:00", "published_display": "11 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Narrative On Evolus (EOLS) Is Resetting After Cautious 2025 And 2026 Guidance", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxOa3pVaGpFMElPXzliRXk5QU4wbW1YVVdUZDNJYVhxUHphSWlfR2NvOFlwVXAxQ0N5QTMyNlhEbmhrTzZwRk55b0pWbE5FSnZXVGlPcHp4OTA1aXFHM09qZ09TTV9EYWotZ3Nkb2VraHdTYURpS1BMX1VUME9CSWZrbGNDY3pPbG90dzdmNzRfTQ?oc=5", "source_name": "Market source", "published_at": "2026-03-12T07:00:00+00:00", "published_display": "12 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Evolus Stock Soared Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMifEFVX3lxTE9kMndhVEtROUpQdHBIM2o0WEtPTmF2U1Ria3k3VVc0cl9FLUxRUUlKTU84WnRMQ0l3TzZrS0xXcm4wUkVsVUZ3Qk41NUk3OXFSWjNoc3ljTlNJVmRUaUpHYlpsbDM3b01zWWU2aXBYUjZwM2k4V25uXzU3dzg?oc=5", "source_name": "The Motley Fool", "published_at": "2026-03-04T08:00:00+00:00", "published_display": "04 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evolus Reports Fourth Quarter and Full-Year 2025 Financial Results; Delivers Sixth Consecutive Year of Double-Digit Growth and Expects Sustainable Profitability1 Beginning in 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1gJBVV95cUxOWWxRWUtoX1l2cDRMV2V1eHQ1SXZidERaQmpZTTlvRUJBbHkyMmNiMGlpYXpRcWo1TFdBLUl3NGtVUmcxbkxkRlQ5cHlkY1NBQWZrRUdjQm91SUdTc1RQTDIyTTlIeTZ5bWxxQUh4RGdJcWs1NXBTMmNIYWJSSFMxOXNITjRNMzB4S3pURXFocDJabnc2eThGbEJYT3dHWldHVWRkUEZLSnFyVFo0MXRJQzhiNGI1Q09ISWg1andZN2JIbzY3enBJSlliNUhxcmtrSHpPdUJkMkNNRHdUcTVDeWs4ZFdadkloajZ5TWdaZThhZVZ0elhaM2MyWENaMjBDZVFicFUtcUd2eFREak5TdjUybjBGQ25RdFZIdGN6aWFQeWVVMFdtLXNzWTdKenFhaUpoSHdtNFB5b0gtZHp3anU3REhUTFVFMEZGUDNVLXdLMzJpLVE?oc=5", "source_name": "Business Wire", "published_at": "2026-03-03T08:00:00+00:00", "published_display": "03 Mar 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evolus Inc. (EOLS) Stock Rises on Q4 2025 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxQNDh4MHBXMXoweXZrb3o3MDhRTVZ4b3Z2Uk5XZmFaQ3BHQ3hJemVxdUtLVUhubl9yOHU4MC1HRWFJMjZDcHMtWUZheDV3Z2VSUGl2ZXFCaTQ4aGp2YW9nOHMzTk1IaEM2bmZHcnA0Mk95ZUk2LXBzd2Y4MkY1YXNzRFJQZXlnblZ3VnpVbTFsTmw?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-03-03T08:00:00+00:00", "published_display": "03 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evolus, Inc. (EOLS) Matches Q4 Earnings Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMifEFVX3lxTE5BWFJpUGhaN05FVkpjR3h4c2wwV2xVMG0teEtEbEdPODljSjZkcFdoSVZvX05DU1BzUGhtWV9XSDZ0Z3RLZWktSW8zNUVhZUsyLXBfQ19QbUdGdVhYbjhPNGdId3pvdTFDZVN1LW1GZ2JnYTRRa1J1aDhzdEw?oc=5", "source_name": "Market source", "published_at": "2026-03-03T08:00:00+00:00", "published_display": "03 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Catalysts Are Rewriting The Evolus (EOLS) Story After The Guidance Reset", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxObUZYeEh6ZWtMampKMkNxb0NkU2ZkSHNPem5keWFGSTZacU02ZVNoU3BvcWQ4TXZpMUVGM0JuNlhnR3VtZWJha0JQb0RDNGM5RThpY2NTQ1NBbUE3YnN5VUdKMVQxcUZzdl91ZlhVM0hSR2JzRWhTODU3N1k2OXdHX0thVktQYXBaWF9z?oc=5", "source_name": "Market source", "published_at": "2026-02-10T08:00:00+00:00", "published_display": "10 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lacklustre Performance Is Driving Evolus, Inc.'s (NASDAQ:EOLS) 30% Price Drop", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-15T08:00:00+00:00", "published_display": "15 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Sellers Might Regret Selling Evolus Shares at a Lower Price Than Current Market Value", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-07T08:00:00+00:00", "published_display": "07 Jan 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evolus: A Difficult 2025 Means I'm Downgrading Stock To 'Hold' For 2026 (NASDAQ:EOLS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPVnI1NndTbElfc3JGczF1R0I3R2JibGYwNExldHFTMEU1R0Jycy0tX0cwMkFvSTE1NG9QUElqQjhaX09KOHJ4eGptTC0zclU2TmFOX3Y5ZzctTVZOcWlPUl9QUnk1QUFDRE5rRl83bTNUbFpRQjlnX1hPUFA1RnFOdDlxYlN0N1pPUVZVU1VWam9Fb2hWdl93cDVqZkEtQQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2025-12-17T08:00:00+00:00", "published_display": "17 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evolus, Inc. (NASDAQ:EOLS): When Will It Breakeven?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-09-16T07:00:00+00:00", "published_display": "16 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evolus Announces Pricing of $50.0 Million Underwritten Offering of Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxNS1ZaLVQtRkZaVlQ2dThjN2ZSM2JLZk85SmNWdS1ZZmV1amhZN2FPazJBTFhDR3RDNkVRWjlhcmhBWDF0MWhjYnBNTndHOXZQM29sLWxlbGFGcVVCOFVPSS03cDJ6Tml4b2ZMSWU0ZjVFb3ZiOVBZOVhQT1FrZXZkeGhxTFJVTmR4cGJ1VXJvVWVMZllqM0dSQnZrUU8wd1BCNlk5cVZJY2gyU0c1RG84dUdKeThlTXEzRzE5MU85UlN1eFowUVdpcWdoMFdYRlZNR3BfTw?oc=5", "source_name": "Business Wire", "published_at": "2024-03-11T07:00:00+00:00", "published_display": "11 Mar 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evolus Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxOcVVIcG9jNHhXVFhDNU1lV1U0TjB2MEg5VTRYRjNuMnV6UEI0OFdYQmRLZGoyNzQwT3pyUDI2ZnNvQk5WV2VGTjZnYVJwOFVmeEM1N1VTUXVHSzRQRjZxeGlwTHVOQktuOGRXNVItc0FDYXk3Qk1aNHg4a2xfYURDeUZRYXVOdkRsWjlRMzA3U2dzQThzWU1SelhrN2hUdmVxVk1ldWVabUxtNG9vRDhpSXBZMnMzWk9JbkR2ckE1UGJHMGVLQTVKR2tPTHF5Z3NDN1h1eVo5WWNpUQ?oc=5", "source_name": "Business Wire", "published_at": "2023-03-08T08:00:00+00:00", "published_display": "08 Mar 2023 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbbVie settles trade secrets fight with Evolus, scoring $35M and royalties on Botox rival Jeuveau", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxNRl85c1NOVGdUZVBGV0E5RGM3bllfd0UyNnd0WjZFRkxPMDZycmVPcGdhY004cGMtb3dacDlvX0Y4TWtqNWFyZFBia254TWRYUUFmVWlRTE1OcFpDeFJySW5BeEE5TEljX3RTYVcyWlJKbDdLTTl3anpVZUk3R0xUNGtLWjdoSC11cW4wUEN2LTlaT3M2Y0o1dGdXX3E1X09aRmVVU2lSamQzLTdsLW0tbEVfUzJWR2xoajVVZl9vSDVTZw?oc=5", "source_name": "Fierce Pharma", "published_at": "2021-02-19T08:00:00+00:00", "published_display": "19 Feb 2021 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evolus (EOLS) Stock Price, News & Analysis $EOLS", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE9NT2daVVpEYjN3LTR6Z291NVctbndfOFBlOTVibDczTTBHWThxZjFseXZmaVJicXZlNmlCT2JKQWV3ZHh1N2tFYU13clVkQWI1dllERzdmVW95UQ?oc=5", "source_name": "MarketBeat", "published_at": "2018-02-12T11:49:44+00:00", "published_display": "12 Feb 2018 11:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Analysts Conflicted on These Healthcare Names: Irhythm Technologies (IRTC), Penumbra (PEN) and Evolus (EOLS)", "summary": "This article highlights recent analyst ratings for several healthcare companies. Irhythm Technologies (IRTC) received a \"Strong Buy\" consensus with a significant upside, while Penumbra (PEN) garnered a \"Hold\" consensus. Evolus (EOLS) also received a \"Strong Buy\" consensus rating ", "url": "https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/3293172/analysts-conflicted-on-these-healthcare-names-irhythm-technologies-irtc-penumbra-pen-and-evolus-eols/", "source_name": "The Globe and Mail", "published_at": "2026-07-15T12:12:27", "published_display": "15 Jul 2026 12:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evolus issues stock-based hiring incentives to 38 new employees", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQU0dmSzJoQ2xVRDdMTm54TmVqQWV2VnR4Nm9Kbm1FTUZWdnp0Q28wWUtTTU9HT0RFR3ZvMXFWNk55eXFOTGRiaDdiWEZ4LXpDQWpNZ2wtVVhYUUxvVnQtUmVyQUdJcEdLYUsyUUY4NUJ3VllSVEN0UUtNZlM2cnh2Y2ZjX2wtaFlnbExZQTRxV3ZpdHU4Rm1sN3RoRGd3MmJnNVlpRDRERWU2TnhGajVRc19naHhfSVlmVGJMOA?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-10T20:05:00+00:00", "published_display": "10 Jul 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "Evolus, Inc. announced the grant of 115,000 restricted stock units (RSUs) to 38 newly hired non-executive employees between April and July 2026. These inducement awards were approved by the compensation committee under Evolus' 2023 Inducement Incentive Plan, as material inducemen", "url": "https://ca.finance.yahoo.com/news/evolus-reports-inducement-grants-under-200500197.html", "source_name": "Yahoo! Finance Canada", "published_at": "2026-07-10T16:05:00", "published_display": "10 Jul 2026 16:05", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evolus Class Action Reminder", "summary": "Faruqi & Faruqi, LLP is reminding investors who suffered losses exceeding $100,000 in Evolus (NASDAQ: EOLS) stock or options between February 1, 2019, and July 6, 2020, to contact them. The firm is investigating potential claims that Evolus made misleading statements regarding it", "url": "https://www.newsfilecorp.com/release/69495?lang=fr", "source_name": "TMX Newsfile", "published_at": "2026-07-10T08:39:56", "published_display": "10 Jul 2026 08:39", "sentiment": "negative", "sentiment_pct": 28, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in Evolus, Inc. Stocks", "summary": "This article lists various ETFs that invest in Evolus, Inc. (EVL) stocks, providing details such as market value, weight, issuer, management style, expense ratio, and AUM. The funds primarily focus on small-cap, total market, micro-cap, and healthcare sectors, offering investors ", "url": "https://www.tradingview.com/symbols/FWB-EVL/etfs/", "source_name": "TradingView", "published_at": "2026-07-09T08:40:45", "published_display": "09 Jul 2026 08:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evolus Partners With IBSA to Develop, Commercialize Profhilo in US", "summary": "Evolus has partnered with IBSA to develop and commercialize Profhilo, an injectable aesthetic treatment, in the United States. This collaboration aims to bring a new bio-remodeling product to the US market, expanding Evolus's portfolio beyond neuromodulators and adding an immedia", "url": "https://www.moomoo.com/news/post/72656750/evolus-partners-with-ibsa-to-develop-commercialize-profhilo-in-us", "source_name": "Moomoo", "published_at": "2026-07-09T03:39:41", "published_display": "09 Jul 2026 03:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evolus, IBSA Partner to Develop and Commercialize Skin Quality Filler in the US", "summary": "Evolus has entered into an exclusive licensing and distribution agreement with IBSA to develop and commercialize Profhilo, a hyaluronic acid-based injectable for skin quality improvement, in the United States. This partnership expands Evolus's presence in the aesthetic market, ta", "url": "https://thedermdigest.com/evolus-ibsa-partner-to-develop-and-commercialize-skin-quality-filler-in-the-us/", "source_name": "The Dermatology Digest", "published_at": "2026-07-08T15:39:43", "published_display": "08 Jul 2026 15:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evolus signs licensing deal for Profhilo skin injectable in US", "summary": "Evolus Inc. has signed an exclusive licensing and distribution agreement with IBSA to commercialize Profhilo, a hyaluronic acid skin injectable, in the United States. This agreement allows Evolus to expand its aesthetic product portfolio, complementing its existing neurotoxin and", "url": "https://www.investing.com/news/company-news/evolus-signs-licensing-deal-for-profhilo-skin-injectable-in-us-93CH-4781771", "source_name": "Investing.com", "published_at": "2026-07-08T13:39:43", "published_display": "08 Jul 2026 13:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evolus signs licensing deal for Profhilo skin injectable in US By Investing.com", "summary": "Evolus Inc. has signed an exclusive licensing and distribution agreement with Swiss pharmaceutical company IBSA to bring Profhilo, a hyaluronic acid skin injectable, to the United States. This strategic move expands Evolus's aesthetic product portfolio, which already includes Jeu", "url": "https://ca.investing.com/news/stock-market-news/evolus-signs-licensing-deal-for-profhilo-skin-injectable-in-us-93CH-4725402", "source_name": "Investing.com Canada", "published_at": "2026-07-08T13:18:04", "published_display": "08 Jul 2026 13:18", "sentiment": "positive", "sentiment_pct": 73, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evolus Secures Exclusive U.S. Profhilo License From IBSA; No Upfronts, 15-Year Term", "summary": "Evolus has secured an exclusive 15-year U.S. license, supply, and distribution agreement with IBSA for Profhilo, an injectable hyaluronic acid product for skin quality. Evolus will manage the U.S. development, clinical work, and regulatory approval, with no upfront or milestone p", "url": "https://www.tradingview.com/news/tradingview:1ae7b95f4c814:0-evolus-secures-exclusive-u-s-profhilo-license-from-ibsa-no-upfronts-15-year-term/", "source_name": "TradingView", "published_at": "2026-07-08T13:13:04", "published_display": "08 Jul 2026 13:13", "sentiment": "positive", "sentiment_pct": 71, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evolus adds Profhilo, a skin-quality injectable sold in 70+ countries", "summary": "Evolus, Inc. announced an exclusive licensing and distribution agreement with IBSA to bring Profhilo\u00ae, a leading skin-quality injectable, to the United States. This partnership expands Evolus's injectable portfolio into the rapidly growing skin quality segment, complementing its ", "url": "https://www.stocktitan.net/news/EOLS/evolus-announces-partnership-with-ibsa-to-develop-and-commercialize-vtkgy75cjupb.html", "source_name": "Stock Titan", "published_at": "2026-07-08T13:12:04", "published_display": "08 Jul 2026 13:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evolus Announces Partnership with IBSA to Develop and Commercialize Market-Leading Profhilo\u00ae in the United States, Expanding Its Injectable Portfolio into Skin Quality", "summary": "Evolus, Inc. has partnered with IBSA to exclusively license and commercialize Profhilo\u00ae in the United States, expanding Evolus's injectable portfolio into the skin quality segment. Profhilo\u00ae is a market-leading injectable in Europe designed to improve skin quality, hydration, ela", "url": "https://ca.finance.yahoo.com/news/evolus-announces-partnership-ibsa-develop-130000914.html", "source_name": "Yahoo! Finance Canada", "published_at": "2026-07-08T09:00:00", "published_display": "08 Jul 2026 09:00", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(EOLS) and the Role of Price-Sensitive Allocations", "summary": "This article provides an analysis of Evolus Inc. (NASDAQ: EOLS) based on AI-generated signals for July 7, 2026. It highlights a near-term weak sentiment but mid-term strength within a broader long-term weak bias, noting compelling upside potential due to the absence of resistance", "url": "https://news.stocktradersdaily.com/news_release/52/EOLS_and_the_Role_of_Price-Sensitive_Allocations_070726031602_1783408562.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-07T03:16:49", "published_display": "07 Jul 2026 03:16", "sentiment": "negative", "sentiment_pct": 35, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EOLS - Evolus Inc Options", "summary": "This page provides a detailed financial overview of Evolus Inc (EOLS) options, including its latest stock price, financial metrics, and performance indicators. It covers market capitalization, income, sales, various ratios, insider ownership, institutional ownership, profitabilit", "url": "https://finviz.com/quote?t=EOLS&ta=1&p=m&ty=oc&r=y5&ov=list_strike&s=2.5", "source_name": "Finviz", "published_at": "2026-07-06T19:11:49", "published_display": "06 Jul 2026 19:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Evolus, Inc. Common Stock \u2013 NASDAQ:EOLS", "summary": "This page from TradingView provides financial information for Evolus, Inc. Common Stock (NASDAQ: EOLS), specifically focusing on its enterprise value to EBITDA forward metric. It highlights the company's financial overview within the health technology and pharmaceutical sectors. ", "url": "https://www.tradingview.com/symbols/NASDAQ-EOLS/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T13:09:39", "published_display": "28 Jun 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evolus (EOLS) price target decreased by 11.11% to 14.96", "summary": "The price target for Evolus (EOLS) has been decreased by 11.11%, bringing it down to $14.96. Further details are not available in the provided content.", "url": "http://www.msn.com/en-us/money/topstocks/evolus-eols-price-target-decreased-by-11-11-to-14-96/ar-AA1X5JEh?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "source_name": "MSN", "published_at": "2026-06-28T11:09:27", "published_display": "28 Jun 2026 11:09", "sentiment": "negative", "sentiment_pct": 30, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evolus, Inc. Actuals & Estimates (NASDAQ:EOLS)", "summary": "This article provides actuals and estimates for Evolus, Inc. (NASDAQ:EOLS), including financial data, analyst forecasts, and various stock performance metrics. It covers the company's current stock price, historical highs and lows, volatility, market capitalization, and earnings ", "url": "https://www.tradingview.com/symbols/NASDAQ-EOLS/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T09:11:19", "published_display": "26 Jun 2026 09:11", "sentiment": "positive", "sentiment_pct": 61, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Evolus, Inc. Common Stock \u2013 NASDAQ:EOLS", "summary": "This article provides access to the \"Price to sales forward\" financial metric for Evolus, Inc. Common Stock (NASDAQ: EOLS) on the TradingView platform. It highlights that this data is part of the financials section for EOLS, indicating its availability for users analyzing the com", "url": "https://www.tradingview.com/symbols/NASDAQ-EOLS/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T09:09:46", "published_display": "26 Jun 2026 09:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EOLS Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "The article provides a forecast and price target for Evolus, Inc. (EOLS) stock for 2027, based on analyst ratings and the company's financial performance. It includes current stock price information, historical highs and lows, market capitalization, volatility, and details on ear", "url": "https://www.tradingview.com/symbols/NASDAQ-EOLS/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T16:09:20", "published_display": "25 Jun 2026 16:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evolus Inc (EOLS) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Evolus Inc (EOLS), detailing its price momentum score of 9.32 within the Pharmaceuticals industry. It identifies current support at $6.35 and resistance at $7.55, suggesting suitability for range-bound swing trading. The analysis incl", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-eols/technical", "source_name": "TradingKey", "published_at": "2026-06-24T09:09:20", "published_display": "24 Jun 2026 09:09", "sentiment": "positive", "sentiment_pct": 77, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Evolus (EOLS) Finally Turning the Corner on Profitability", "summary": "Evolus (EOLS) reported strong Q1 2026 results, beating revenue expectations with $73.1 million, driven by demand for Jeuveau and growth in Evolisse. The company achieved its second consecutive quarter of positive Adjusted EBITDA, signaling progress toward full-year profitability ", "url": "https://www.kavout.com/market-lens/is-evolus-eols-finally-turning-the-corner-on-profitability", "source_name": "Kavout", "published_at": "2026-06-21T00:40:43", "published_display": "21 Jun 2026 00:40", "sentiment": "positive", "sentiment_pct": 63, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evolus Inc (EOLS) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Evolus Inc (EOLS) has a financial score of 8.00, placing it 84th out of 157 in the Pharmaceuticals industry, indicating a weak financial status but high operating efficiency. The company reported a quarterly revenue of $73.14M, marking a 6.74% year-over-year increase, and net pro", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-eols/financial-health", "source_name": "TradingKey", "published_at": "2026-06-18T19:09:32", "published_display": "18 Jun 2026 19:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evolus Inc (EOLS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "The article provides a revenue breakdown for Evolus Inc (EOLS). However, it states that relevant data regarding business segments, regional revenue, and profit contribution have not been disclosed by the company yet. The page displays current stock information for EOLS, including", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-eols/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T11:40:39", "published_display": "18 Jun 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evolus Inc (EOLS) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Evolus Inc (EOLS), identifying major shareholders by proportion and type, as well as institutional holdings over various quarters. It highlights key individual and institutional investors and their recent activities, alongside rel", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-eols/ownership", "source_name": "TradingKey", "published_at": "2026-06-18T11:40:39", "published_display": "18 Jun 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evolus Inc (EOLS) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Evolus Inc (EOLS) has an earnings forecast score of 8.57, ranking 28th in the Pharmaceuticals industry. Analysts have a consensus \"Buy\" rating for EOLS, with an average price target of $19.50, suggesting a significant upside of over 121% from its current price of $6.63. The expec", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-eols/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T06:40:44", "published_display": "18 Jun 2026 06:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EOLS Reiterated by BTIG -- Price Target Maintained at $13.00", "summary": "BTIG has reiterated a Buy rating for Evolus (EOLS), maintaining a price target of $13.00. Despite strong growth potential (GF Score Growth 10/10), the company faces challenges in Financial Strength and Profitability (both 3/10). The stock is considered 51.0% undervalued by GuruFo", "url": "https://www.gurufocus.com/news/8920352/eols-reiterated-by-btig-price-target-maintained-at-1300", "source_name": "GuruFocus", "published_at": "2026-06-17T11:10:39", "published_display": "17 Jun 2026 11:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evolus Inc (EOLS) Institutional Confidence", "summary": "Evolus Inc (EOLS) has an institutional shareholding score of 7.00, ranking 51st in the Pharmaceuticals industry. The institutional shareholding proportion is 75.98%, a decrease of 14.84% quarter-over-quarter. James Simons is the largest institutional shareholder, with other signi", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-eols/sentiment", "source_name": "TradingKey", "published_at": "2026-06-17T05:40:04", "published_display": "17 Jun 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[EFFECT] Evolus, Inc. SEC Filing", "summary": "This article provides details on an SEC filing (Form EFFECT) by Evolus, Inc. The filing indicates an effectiveness date of June 12, 2026, for Form S-3. It also includes company information, recent news, and other SEC filings for Evolus.", "url": "https://www.stocktitan.net/sec-filings/EOLS/effect-evolus-inc-sec-filing-aca2df6814a4.html", "source_name": "Stock Titan", "published_at": "2026-06-15T10:39:29", "published_display": "15 Jun 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Understanding the Setup: (EOLS) and Scalable Risk", "summary": "This article provides an analysis of Evolus Inc. (NASDAQ: EOLS) using AI models to suggest trading strategies. It highlights mixed sentiment, potential upside due to lack of resistance, and offers specific position trading, momentum breakout, and risk hedging strategies. The anal", "url": "https://news.stocktradersdaily.com/news_release/89/Understanding_the_Setup:_EOLS_and_Scalable_Risk_061526125602_1781499362.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-15T00:56:00", "published_display": "15 Jun 2026 00:56", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evolus shareholders re-elect directors and approve executive compensation", "summary": "Evolus Inc. shareholders re-elected Brady Stewart and Vikram Malik as Class II directors for three-year terms and ratified Ernst & Young LLP as the independent public accounting firm. Shareholders also approved the compensation of the company\u2019s named executive officers in an advi", "url": "https://www.investing.com/news/sec-filings/evolus-shareholders-reelect-directors-and-approve-executive-compensation-93CH-4740826", "source_name": "Investing.com", "published_at": "2026-06-14T19:09:32", "published_display": "14 Jun 2026 19:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evolus (EOLS) shareholders approve directors, auditor and say-on-pay at 2026 meeting", "summary": "At its Annual Meeting of Stockholders held on June 11, 2026, Evolus, Inc. (EOLS) shareholders elected Brady Stewart and Vikram Malik as Class II directors, with terms extending until the 2029 annual meeting. They also ratified Ernst & Young LLP as the independent registered publi", "url": "https://www.stocktitan.net/sec-filings/EOLS/8-k-evolus-inc-reports-material-event-7482311af61b.html", "source_name": "Stock Titan", "published_at": "2026-06-12T20:38:50", "published_display": "12 Jun 2026 20:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evolus Plans to Launch Estyme Collection in Europe", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/evolus-plans-launch-estyme-collection-142513501.html", "source_name": "MT Newswires", "published_at": "2026-05-11T14:25:13+00:00", "published_display": "11 May 2026 14:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evolus to launch Estyme dermal filler line in Europe on May 16", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOVnJrTVVySFlqQUFTbTVuQVNXVUtNZGp5bDZBWG1zbF9Rd0E1V1ZyZWxqTnB4Qk81UzF1S2d1VUFLYmdyUXBPWEpjR3BaNGlkTVlkUDJteHpuMjF3cGQycU9iem5uajNqQk1jSFVNYTNsbkdZUXZLZFlKZWpsejEwWVdwb1V1NWRjaGt2OWc3eVdKa1FMdzlHSDFGQTMyeWo2U3AwQ1RScFZub25DRHRfdUJlQ1gtTThvQ1Y4?oc=5", "source_name": "Investing.com", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evolus, Inc. Q1 2026 Earnings Call Summary", "summary": "", "url": "https://finance.yahoo.com/m/02339c0c-0620-3614-a7ae-b68d46cb3b0b/evolus%2C-inc.-q1-2026-earnings.html", "source_name": "Moby", "published_at": "2026-05-05T00:23:54+00:00", "published_display": "05 May 2026 00:23", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evolus Q1 Earnings Call Highlights", "summary": "", "url": "https://finance.yahoo.com/m/a1fbc5e2-9ec3-3a6c-8d00-3977a3afbf67/evolus-q1-earnings-call.html", "source_name": "MarketBeat", "published_at": "2026-05-04T22:17:52+00:00", "published_display": "04 May 2026 22:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evolus (EOLS) Q1 2026 Earnings Transcript", "summary": "", "url": "https://finance.yahoo.com/m/61dbbb24-c13d-35a2-856d-7bbf930dce7a/evolus-%28eols%29-q1-2026.html", "source_name": "Motley Fool", "published_at": "2026-05-04T21:53:43+00:00", "published_display": "04 May 2026 21:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evolus (EOLS) Q2 2025 Earnings Call Transcript", "summary": "", "url": "https://finance.yahoo.com/m/97448adc-f08c-361f-8fda-4e68842d74db/evolus-%28eols%29-q2-2025.html", "source_name": "Motley Fool", "published_at": "2026-05-04T20:34:49+00:00", "published_display": "04 May 2026 20:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evolus Reports First Quarter 2026 Financial Results; Company Delivers Second Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year Outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwJBVV95cUxNRS1sSEUyQlRsNzlPNk5zRG4zNlJLU3U2NlBhYmdRc0V1cmFyZ0ZZWG53aW5lTFRybkFwMXduNUtFYl80WmJMRkQ1c1RiUmRtSklQWjR4SlJ3blpIWkx6RUNjQ19pbVdrdl8zXzBtYUtEdGwwaWJpMURIV3MwcDJqblpZYlRLa1A5eHVBcC1iaUozTDBHWTZKMnJfMlJQZkNsb1AwY0dYUElxanlRazRRQU5oUFktcnlibEpRU19iWE1abVBQT1BXbXVtTjRwS3pTSjI1ejd1ZUM3dzMwTHpWTWRYZExiRmFxbll4SWUxbTRRV0FnSEVxdHdMZ0hacWtZdXk3LVpPdHlVeHd1QUZSSXJxS1dxNng2ekp6REQ3cjROMVdZQUgzQnRKbzNCSzZUMDVwZFVYSQ?oc=5", "source_name": "Business Wire", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evolus, Inc. (EOLS) Reports Q1 Loss, Tops Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxQbVpHZS1CTWVmeG1zbFdCT0Y0U2JfcWkxU05HOWdCb0FpeUdULWZMV1VVdE8tRXp0WFVrdkJzRWpWU19jVmxvc1ZKRXlqWWZQM3IwYzRRaXBEeFkwR09EU2dsenZxblczcDJHSnZSYzNiSzNrNVdWY1VPWUhQMUJUeU4tMEc5c015T0hEM0MxdkpFTTZPVXc?oc=5", "source_name": "Market source", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evolus Inc. (EOLS) stock falls on Q1 2026 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxQYjZXRF9ZTG1sRWQ5bmhpbWllSnkzbHFCUDVjaUxNVUxJWEhfeERpOXkyaHBZOHB5ekdEbHA5RW9ZWDBhVFFvbFluTFlRM0NOSTZwU2JjTjJUeFdWbmhLLVdCVS1QNlpYem5TWnRaX2dJOHlTcVJDTk9reEpVU01BN2dOS0NtMHZad1hCUjRlMGo?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 22, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Evolus (EOLS) Story Is Shifting As Analysts Reset Growth And Valuation Assumptions", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxNcFJsUG1iQnVVamM1UW1ldm5LdVFZVnpaMlZhOWp5YU9jMmZuQjVGa3NROFJtZWJzdFNSV1lfcWZqTXV3MkRtU2V4SkxTc0xJSkZaV3M5Rm40N0dMVnhRSWhxbWlDNk1MZ2Fja0pGb1ZLM2JqNjJvU09JZkNEZ3hpTEhlVHR5anRPZks4ZlR2SHQ5SGFVbl9JQS0ydWN1Tkl1UVE?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Evolus (EOLS) Investment Story Is Shifting After Softer Guidance And Target Cuts", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQd3NJMzFxckwtRUZ3T1pEb1BlUVA3YkUxWXdqM3ppYTluTEdBUFJFUkdoVGFZR2hpZnQ3R1ZabDFQajdvZHZNdWhBTEhBQnJwTVQ0NWpJQlNQSGJvZnRMdko1ZjFNUTBLVWtxbE9iVzdUYmIyMElQUjFpbDF6bGpTeU5aZHhtXzg5aFltY1E4eFFHWGFyQUY0NlpzVWZIRVRxQnhvTw?oc=5", "source_name": "Market source", "published_at": "2026-04-11T07:00:00+00:00", "published_display": "11 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Narrative On Evolus (EOLS) Is Resetting After Cautious 2025 And 2026 Guidance", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxOa3pVaGpFMElPXzliRXk5QU4wbW1YVVdUZDNJYVhxUHphSWlfR2NvOFlwVXAxQ0N5QTMyNlhEbmhrTzZwRk55b0pWbE5FSnZXVGlPcHp4OTA1aXFHM09qZ09TTV9EYWotZ3Nkb2VraHdTYURpS1BMX1VUME9CSWZrbGNDY3pPbG90dzdmNzRfTQ?oc=5", "source_name": "Market source", "published_at": "2026-03-12T07:00:00+00:00", "published_display": "12 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Evolus Stock Soared Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMifEFVX3lxTE9kMndhVEtROUpQdHBIM2o0WEtPTmF2U1Ria3k3VVc0cl9FLUxRUUlKTU84WnRMQ0l3TzZrS0xXcm4wUkVsVUZ3Qk41NUk3OXFSWjNoc3ljTlNJVmRUaUpHYlpsbDM3b01zWWU2aXBYUjZwM2k4V25uXzU3dzg?oc=5", "source_name": "The Motley Fool", "published_at": "2026-03-04T08:00:00+00:00", "published_display": "04 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evolus Reports Fourth Quarter and Full-Year 2025 Financial Results; Delivers Sixth Consecutive Year of Double-Digit Growth and Expects Sustainable Profitability1 Beginning in 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1gJBVV95cUxOWWxRWUtoX1l2cDRMV2V1eHQ1SXZidERaQmpZTTlvRUJBbHkyMmNiMGlpYXpRcWo1TFdBLUl3NGtVUmcxbkxkRlQ5cHlkY1NBQWZrRUdjQm91SUdTc1RQTDIyTTlIeTZ5bWxxQUh4RGdJcWs1NXBTMmNIYWJSSFMxOXNITjRNMzB4S3pURXFocDJabnc2eThGbEJYT3dHWldHVWRkUEZLSnFyVFo0MXRJQzhiNGI1Q09ISWg1andZN2JIbzY3enBJSlliNUhxcmtrSHpPdUJkMkNNRHdUcTVDeWs4ZFdadkloajZ5TWdaZThhZVZ0elhaM2MyWENaMjBDZVFicFUtcUd2eFREak5TdjUybjBGQ25RdFZIdGN6aWFQeWVVMFdtLXNzWTdKenFhaUpoSHdtNFB5b0gtZHp3anU3REhUTFVFMEZGUDNVLXdLMzJpLVE?oc=5", "source_name": "Business Wire", "published_at": "2026-03-03T08:00:00+00:00", "published_display": "03 Mar 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evolus Inc. (EOLS) Stock Rises on Q4 2025 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxQNDh4MHBXMXoweXZrb3o3MDhRTVZ4b3Z2Uk5XZmFaQ3BHQ3hJemVxdUtLVUhubl9yOHU4MC1HRWFJMjZDcHMtWUZheDV3Z2VSUGl2ZXFCaTQ4aGp2YW9nOHMzTk1IaEM2bmZHcnA0Mk95ZUk2LXBzd2Y4MkY1YXNzRFJQZXlnblZ3VnpVbTFsTmw?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-03-03T08:00:00+00:00", "published_display": "03 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evolus, Inc. (EOLS) Matches Q4 Earnings Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMifEFVX3lxTE5BWFJpUGhaN05FVkpjR3h4c2wwV2xVMG0teEtEbEdPODljSjZkcFdoSVZvX05DU1BzUGhtWV9XSDZ0Z3RLZWktSW8zNUVhZUsyLXBfQ19QbUdGdVhYbjhPNGdId3pvdTFDZVN1LW1GZ2JnYTRRa1J1aDhzdEw?oc=5", "source_name": "Market source", "published_at": "2026-03-03T08:00:00+00:00", "published_display": "03 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Catalysts Are Rewriting The Evolus (EOLS) Story After The Guidance Reset", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxObUZYeEh6ZWtMampKMkNxb0NkU2ZkSHNPem5keWFGSTZacU02ZVNoU3BvcWQ4TXZpMUVGM0JuNlhnR3VtZWJha0JQb0RDNGM5RThpY2NTQ1NBbUE3YnN5VUdKMVQxcUZzdl91ZlhVM0hSR2JzRWhTODU3N1k2OXdHX0thVktQYXBaWF9z?oc=5", "source_name": "Market source", "published_at": "2026-02-10T08:00:00+00:00", "published_display": "10 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lacklustre Performance Is Driving Evolus, Inc.'s (NASDAQ:EOLS) 30% Price Drop", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-15T08:00:00+00:00", "published_display": "15 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Sellers Might Regret Selling Evolus Shares at a Lower Price Than Current Market Value", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-07T08:00:00+00:00", "published_display": "07 Jan 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evolus: A Difficult 2025 Means I'm Downgrading Stock To 'Hold' For 2026 (NASDAQ:EOLS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPVnI1NndTbElfc3JGczF1R0I3R2JibGYwNExldHFTMEU1R0Jycy0tX0cwMkFvSTE1NG9QUElqQjhaX09KOHJ4eGptTC0zclU2TmFOX3Y5ZzctTVZOcWlPUl9QUnk1QUFDRE5rRl83bTNUbFpRQjlnX1hPUFA1RnFOdDlxYlN0N1pPUVZVU1VWam9Fb2hWdl93cDVqZkEtQQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2025-12-17T08:00:00+00:00", "published_display": "17 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evolus, Inc. (NASDAQ:EOLS): When Will It Breakeven?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-09-16T07:00:00+00:00", "published_display": "16 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evolus Announces Pricing of $50.0 Million Underwritten Offering of Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxNS1ZaLVQtRkZaVlQ2dThjN2ZSM2JLZk85SmNWdS1ZZmV1amhZN2FPazJBTFhDR3RDNkVRWjlhcmhBWDF0MWhjYnBNTndHOXZQM29sLWxlbGFGcVVCOFVPSS03cDJ6Tml4b2ZMSWU0ZjVFb3ZiOVBZOVhQT1FrZXZkeGhxTFJVTmR4cGJ1VXJvVWVMZllqM0dSQnZrUU8wd1BCNlk5cVZJY2gyU0c1RG84dUdKeThlTXEzRzE5MU85UlN1eFowUVdpcWdoMFdYRlZNR3BfTw?oc=5", "source_name": "Business Wire", "published_at": "2024-03-11T07:00:00+00:00", "published_display": "11 Mar 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evolus Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxOcVVIcG9jNHhXVFhDNU1lV1U0TjB2MEg5VTRYRjNuMnV6UEI0OFdYQmRLZGoyNzQwT3pyUDI2ZnNvQk5WV2VGTjZnYVJwOFVmeEM1N1VTUXVHSzRQRjZxeGlwTHVOQktuOGRXNVItc0FDYXk3Qk1aNHg4a2xfYURDeUZRYXVOdkRsWjlRMzA3U2dzQThzWU1SelhrN2hUdmVxVk1ldWVabUxtNG9vRDhpSXBZMnMzWk9JbkR2ckE1UGJHMGVLQTVKR2tPTHF5Z3NDN1h1eVo5WWNpUQ?oc=5", "source_name": "Business Wire", "published_at": "2023-03-08T08:00:00+00:00", "published_display": "08 Mar 2023 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AbbVie settles trade secrets fight with Evolus, scoring $35M and royalties on Botox rival Jeuveau", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxNRl85c1NOVGdUZVBGV0E5RGM3bllfd0UyNnd0WjZFRkxPMDZycmVPcGdhY004cGMtb3dacDlvX0Y4TWtqNWFyZFBia254TWRYUUFmVWlRTE1OcFpDeFJySW5BeEE5TEljX3RTYVcyWlJKbDdLTTl3anpVZUk3R0xUNGtLWjdoSC11cW4wUEN2LTlaT3M2Y0o1dGdXX3E1X09aRmVVU2lSamQzLTdsLW0tbEVfUzJWR2xoajVVZl9vSDVTZw?oc=5", "source_name": "Fierce Pharma", "published_at": "2021-02-19T08:00:00+00:00", "published_display": "19 Feb 2021 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evolus (EOLS) Stock Price, News & Analysis $EOLS", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE9NT2daVVpEYjN3LTR6Z291NVctbndfOFBlOTVibDczTTBHWThxZjFseXZmaVJicXZlNmlCT2JKQWV3ZHh1N2tFYU13clVkQWI1dllERzdmVW95UQ?oc=5", "source_name": "MarketBeat", "published_at": "2018-02-12T11:49:44+00:00", "published_display": "12 Feb 2018 11:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 85, "total_relevant": 56, "sentiment_summary": {"positive": 17, "negative": 7, "neutral": 32, "score": 54, "total": 56, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 77, "events": [{"event": "general", "label": "Market update", "weight": 15.2, "count": 27}, {"event": "earnings", "label": "Earnings", "weight": 8.8, "count": 16}, {"event": "deals", "label": "Deals and strategy", "weight": 2.75, "count": 5}, {"event": "analyst", "label": "Analyst action", "weight": 2.2, "count": 4}, {"event": "guidance", "label": "Guidance", "weight": 1.65, "count": 3}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}], "positive_events": 17, "negative_events": 7}, "market_context": {"has_market_context": true, "latest_close": 6.61, "latest_week": "2026-07-10", "one_week_move": -4.2, "four_week_move": -1.8, "twelve_week_move": 40.9, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.208372, "market_dynamics_buy_signal": false, "relative_strength": -9.56554, "fair_value_gap": -33.8, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 43.9037, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-4.2% over one week, -1.8% over four weeks, trend active, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 62, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 6}, {"label": "TradingKey", "count": 6}, {"label": "Market source", "count": 6}, {"label": "Stock Titan", "count": 4}, {"label": "Business Wire", "count": 4}, {"label": "Investing.com", "count": 3}, {"label": "simplywall.st", "count": 3}, {"label": "Yahoo! Finance Canada", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 56}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 27}, {"label": "Earnings", "count": 16}, {"label": "Deals and strategy", "count": 5}, {"label": "Analyst action", "count": 4}, {"label": "Guidance", "count": 3}, {"label": "Regulatory and legal", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "54/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "77/100 classification confidence."}, {"label": "Company focus", "value": "56", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-4.2% over one week, -1.8% over four weeks, trend active, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Analysts Conflicted on These Healthcare Names: Irhythm Technologies (IRTC), Penumbra (PEN) and Evolus (EOLS)"}], "updated_at": "2026-07-16T07:04:10.259166+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}